About: Drug repurposing: Discovery of troxipide analogs as potent antitumor agents

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug repurposing: Discovery of troxipide analogs as potent antitumor agents Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Drug repurposing: Discovery of troxipide analogs as potent antitumor agents
Creator	Wang, Shuai Huo, Jin-Ling Liu, Hong-Min Lu, Nan Yuan, Xiao-Han
source	Elsevier; Medline; PMC
abstract	Drug repurposing plays a vital role in the discovery of undescribed bioactivities in clinical drugs. Based on drug repurposing strategy, we for the first time reported a novel series of troxipide analogs and then evaluated their antiproliferative activity against MCF-7, PC3, MGC-803, and PC9 cancer cell lines and WPMY-1, most of which showed obvious selectivity toward PC-3 over the other three cancer cell lines and WPMY-1. Compound 5q, especially, could effectively inhibit PC3 with an IC(50) value of 0.91 μM, which exhibited around 53-fold selectivity toward WPMY-1. Data indicated that 5q effectively inhibited the colony formation, suppressed the cell migration, and induced G1/S phase arrest in PC3 cells. Also, compound 5q induced cell apoptosis by activating the two apoptotic signaling pathways in PC3 cells: death receptor-mediated extrinsic pathway and mitochondria-mediated intrinsic pathway. Compound 5q up-regulated the expression of both pro-apoptotic Bax and P53, while down-regulated anti-apoptotic Bcl-2 expression. Besides, compound 5q significantly increased the expression of cleaved caspase 3/9 and cleaved PARP. Therefore, the successful discovery of compound 5q may further validate the feasibility of this theory, which will encourage researchers to reveal undescribed bioactivities in traditional drugs.
has issue date	2020-09-15(xsd:dateTime)
bibo:doi	10.1016/j.ejmech.2020.112471
bibo:pmid	32619887
has license	no-cc
sha1sum (hex)	6189dc982069039b276f4456c11f62adb2fc8752
schema:url	https://doi.org/10.1016/j.ejmech.2020.112471
resource representing a document's title	Drug repurposing: Discovery of troxipide analogs as potent antitumor agents
has PubMed Central identifier	PMC7319647
has PubMed identifier	32619887
schema:publication	Eur J Med Chem
resource representing a document's body	covid:6189dc982069039b276f4456c11f62adb2fc8752#body_text
is schema:about of	named entity 'Data' named entity 'cell migration' named entity 'WPMY' named entity 'evaluated' named entity 'compound' named entity 'cells' named entity 'PC3' named entity 'compound' named entity 'REPORTED' named entity 'THEIR' named entity 'STRATEGY' named entity 'NOVEL' named entity 'PC-3' named entity 'SERIES' named entity 'INDICATED' named entity 'SUCCESSFUL' named entity 'APOPTOTIC SIGNALING' named entity 'COMPOUND' named entity 'DISCOVERY' named entity 'extrinsic pathway' named entity 'MCF-7' named entity 'vital' named entity 'pro-apoptotic' named entity 'cleaved' named entity 'PC3' named entity 'analogs' named entity 'antiproliferative' named entity 'anti-apoptotic' named entity 'PC3' named entity 'PARP' named entity 'bioactivities' named entity 'signaling pathways' named entity 'cell lines' named entity 'dose-dependent manner' named entity 'DMSO' named entity 'p27' named entity 'HRMS' named entity 'lung cancer' named entity 'western blotting' named entity 'WPMY' named entity 'Hoechst 33342' named entity 'inhibitory activity' named entity 'cell line' named entity 'analog' named entity 'PC3' named entity 'proapoptotic' named entity 'apoptosis' named entity 'PC3' named entity 'troxipide' named entity 'cancer cell lines' named entity 'tumor' named entity 'Phenyl group' named entity 'Remdesivir' named entity 'n-pentane' named entity 'intrinsic pathway' named entity 'wound healing' named entity 'gastric cancer' named entity 'PARP' named entity 'PARP' named entity 'troxipide' named entity 'pyrimidines' named entity '5-Fu' named entity 'drug repurposing' named entity 'antitumor' named entity 'WPMY' named entity 'MCF-7' named entity 'methyl group' named entity 'Qingdao' named entity 'Bcl-2' named entity 'troxipide' named entity 'PC3' named entity 'structural modification' named entity 'ROS' named entity 'UV light' named entity 'antitumor' named entity 'pyrimidine' named entity 'antiproliferative'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software